Passage Bio Inc
Research Passage Bio Inc (PASG) on Bullrun: market cap USD 14.64M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPASG
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 14.64M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 7.82M
- Free cash flow-USD 9.18M
Valuation Snapshot
latest market cap is USD 14.64M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 46.00M | -USD 31.51M | n/a | -14.35 | USD 46.30M | USD 24.01M | USD 18.76M |
| FY2024 | USD 0 | -USD 65.00M | -USD 47.99M | n/a | -21.04 | USD 37.57M | USD 25.48M | USD 61.26M |
| FY2023 | USD 0 | -USD 102.06M | -USD 78.41M | n/a | -1.86 | USD 21.71M | USD 26.29M | USD 111.28M |
| FY2022 | USD 0 | -USD 136.13M | -USD 123.48M | n/a | -2.5 | USD 34.60M | USD 27.11M | USD 201.37M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 14.64M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 36.82M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 35.19M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 55.49M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 75.28M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 344.45M | n/a | n/a | n/a |
About Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Passage Bio Inc's market cap?
Passage Bio Inc's market capitalization is USD 14.64M.
What does Passage Bio Inc do?
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease.